Liberum Capital restated their hold rating on shares of Genus (LON:GNS) in a research report sent to investors on Monday morning. Liberum Capital currently has a GBX 2,100 ($29.01) price target on the stock.
GNS has been the topic of a number of other research reports. N+1 Singer raised shares of Genus to a buy rating and raised their price target for the stock from GBX 1,844 ($25.48) to GBX 2,485 ($34.33) in a report on Monday, October 30th. Kepler Capital Markets initiated coverage on shares of Genus in a report on Tuesday, November 7th. They issued a hold rating and a GBX 2,353 ($32.51) price target on the stock. Finally, Peel Hunt reaffirmed a buy rating and issued a GBX 2,600 ($35.92) target price on shares of Genus in a research report on Wednesday, November 15th. Four equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. Genus has a consensus rating of Hold and an average target price of GBX 2,270.60 ($31.37).
Genus (GNS) opened at GBX 2,316 ($32.00) on Monday. The company has a market capitalization of $1,430.00 and a P/E ratio of 4,369.81. Genus has a 12-month low of GBX 1,652 ($22.82) and a 12-month high of GBX 2,597 ($35.88).
In other news, insider Karim Bitar sold 32,292 shares of the firm’s stock in a transaction dated Thursday, December 28th. The shares were sold at an average price of GBX 2,511 ($34.69), for a total value of £810,852.12 ($1,120,270.96). Also, insider Stephen Wilson sold 1,625 shares of the firm’s stock in a transaction dated Tuesday, December 19th. The stock was sold at an average price of GBX 2,552 ($35.26), for a total transaction of £41,470 ($57,294.83).
TRADEMARK VIOLATION NOTICE: “Liberum Capital Reaffirms “Hold” Rating for Genus (GNS)” was originally published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this report on another site, it was stolen and republished in violation of U.S. & international copyright & trademark law. The original version of this report can be read at https://www.dispatchtribunal.com/2018/02/15/liberum-capital-reaffirms-hold-rating-for-genus-gns-2.html.
Genus plc is an animal genetics company, which provides farmers with genetics that enable them to produce animal protein, in the form of meat and milk. The Company’s segments include Genus PIC, Genus ABS, Genus Asia, and Research and Development. The Genus PIC segment is engaged in porcine sales business, excluding Asia, and serves porcine customers in North America, Latin America and Europe.
Receive News & Ratings for Genus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genus and related companies with MarketBeat.com's FREE daily email newsletter.